According to this paper[1], prior work has already established that 42% of the dose variance is controlled by 3 SNPs. It isn't 100%, but 42% is not insignificant.
In January 2010 the FDA updated warfarin's label to say
that information on these variants can assist physicians in
selecting a starting dose of the drug. The agency also
provided initial dosage recommendations for patients with
different variant combinations. The FDA does not, however,
require that genetic testing be done before prescribing
warfarin.
[1]: http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Search&db=p...
edit: Also on 23andMe's page regarding Wafarin: